Note: This document contains side effect information about erenumab. Some dosage forms listed on this page may not apply to the brand name Aimovig.
Applies to erenumab: subcutaneous solution.
Serious side effects of Aimovig
Along with its needed effects, erenumab (the active ingredient contained in Aimovig) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking erenumab:
Less common
- Constipation
Incidence not known
- Blurred vision
- cough
- dizziness
- fast heartbeat
- fever
- headache
- hives, itching, skin rash
- hoarseness
- irritation
- joint pain, stiffness, or swelling
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- nervousness
- pounding in the ears
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- slow or fast heartbeat
- tightness in the chest
- trouble breathing or swallowing
- unusual tiredness or weakness
Other side effects of Aimovig
Some side effects of erenumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
Less common
- Muscle cramp or spasm
For Healthcare Professionals
Applies to erenumab: subcutaneous solution.
General
The more commonly reported adverse reactions have included injection site reactions and constipation.[Ref]
Hypersensitivity
Postmarketing reports: Hypersensitivity reactions including rash, angioedema, and anaphylaxis
Gastrointestinal
Common (1% to 10%): Constipation
Postmarketing reports: Constipation with serious complications, oral mucosal ulceration
During clinical trials, constipation was reported in 3% of patients receiving 140 mg/month and 1% of patients receiving 70 mg/month. In the postmarketing period, serious complications of constipation have been reported. In most cases of serious constipations, this drug was discontinued.
Cardiovascular
Postmarketing reports: Hypertension and worsening of preexisting hypertension
Local
Common (1% to 10%): Injection site reactions
Frequency not reported: Injection site erythema, injection site pruritus, injection site pain
Injection site reactions included reports such as injection site pain and injection site erythema. Injection site reactions were reported in 6%, 5%, and 3% of patients receiving 70 mg/month, 140 mg/month, and placebo, respectively.
Musculoskeletal
Common (1% to 10%): Cramps, muscle spasms
Other
Common (1% to 10%): Fatigue
Dermatologic
Common (1% to 10%): Pruritus
Postmarketing reports: Alopecia, rash